Ginkgo Bioworks Holdings Q3 EPS $(1.08) Beats $(2.71) Estimate, Sales $89.05M Beat $45.00M Estimate

Ginkgo生物科技控股第三季度每股收益为$(1.08)，超出$(2.71)的预期，销售额为8.9亿美元，超过4500万美元的预期

Benzinga · 2024/11/12 14:04

Ginkgo Bioworks Holdings (NYSE:DNA) reported quarterly losses of $(1.08) per share which beat the analyst consensus estimate of $(2.71) by 60.15 percent. This is a 82.61 percent increase over losses of $(6.21) per share from the same period last year. The company reported quarterly sales of $89.05 million which beat the analyst consensus estimate of $45.00 million by 97.88 percent. This is a 60.65 percent increase over sales of $55.43 million the same period last year.

Ginkgo Bioworks Holdings（纽交所: DNA）报告每股亏损1.08美元，超过分析师共识预期的2.71美元，增幅达60.15%。这比去年同期每股亏损6.21美元增加了82.61%。该公司报告季度销售额达到8905万美元，超过分析师共识预期的4500万美元，增幅达97.88%。这比去年同期销售额5543万美元增加了60.65%。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Ginkgo Bioworks Holdings Q3 EPS $(1.08) Beats $(2.71) Estimate, Sales $89.05M Beat $45.00M Estimate

Ginkgo Bioworks Holdings Q3 EPS $(1.08) Beats $(2.71) Estimate, Sales $89.05M Beat $45.00M Estimate

风险及免责提示

声明